ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1073

Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis

Kazuhisa Nozawa1, Takuya Hirai2, Hiroshi Tsushima2, Ken Yamaji3, Naoto Tamura3 and Iwao Sekigawa4, 12-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, 2Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, 3Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, pathogenesis and rheumatoid arthritis, rheumatoid arthritis, synovium

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Aberrant angiogenesis has been considered as one of important factors for pathogenesis of rheumatoid arthritis (RA). Several angiogenetic mediators are reported to be massively expressed in synovial tissues of RA patients. Among the mediators, Notch-1 has been reported as one of important angiogenetic mediators in RA. A series of our previous studies have demonstrated that connective tissue growth factor (CTGF) was highly expressed in synovial tissue of RA. CTGF is a multifunctional cytokine and well known as strong mediator for fibrosis. Although we found that CTGF played an important role for the disease progression of RA by multiple mechanisms such as osteoclastogenesis, CTGF interestingly has also been reported as a potent angiogenetic mediator in other diseases. Therefore, this study was conducted to clarify whether CTGF associates with angiogenesis of RA, especially in terms of relation to Notch-1. Furthermore, the therapeutic efficacy of CTGF blockade for prevention of aberrant angiogenesis was also evaluated in animal model of RA.

Methods:

Synovial tissue samples of RA patients were used for immunohistochemical analysis. CTGF association for angiogenesis was evaluated by tube formation assay and Boyden chamber assay using human umbilical vein endothelial cells (HUVECs) in vitro. CTGF-mediated Notch-1 activation were evaluated by immunofluorescence, immunoblotting, and quantitative RT-PCR analysis in HUVECs. Therapeutic efficacy of CTGF blockade for prevention of increased angiogenesis was evaluated in collagen induced arthritis (CIA) mice by administration of the neutralizing anti-CTGF antibodies.

Results: Synovial tissues of RA patients showed upregulation of Notch-1 pathway indicated by strong expression of Notch-1, Notch-1 transmembrane domain (NICD), and DLL-4. CTGF functioned as angiogenetic mediator and was able to activate Notch-1 signaling pathway in vitro. Administration of neutralizing anti-CTGF antibodies prevented the development of angiogenesis through inhibition of Notch-1 expression in CIA mice.

Conclusion: CTGF is able to mediate activation signal against Notch-1 which has been recently postulated as important factor of angiogenesis in RA. CTGF was considered to play an important role for aberrant angiogenesis of RA in combination with Notch-1. CTGF may become a novel target molecule for treatment of RA as CTGF blockade may ameliorate RA by multiple therapeutic mechanisms including suppression of aberrant angiogenesis.


Disclosure: K. Nozawa, None; T. Hirai, None; H. Tsushima, None; K. Yamaji, None; N. Tamura, None; I. Sekigawa, None.

To cite this abstract in AMA style:

Nozawa K, Hirai T, Tsushima H, Yamaji K, Tamura N, Sekigawa I. Connective Tissue Growth Factor Associates with Angiogenesis through Notch-1 Activation in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/connective-tissue-growth-factor-associates-with-angiogenesis-through-notch-1-activation-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/connective-tissue-growth-factor-associates-with-angiogenesis-through-notch-1-activation-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology